Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
NCT ID: NCT01174407
Last Updated: 2010-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
120 participants
OBSERVATIONAL
2008-09-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapy of Age-related Macular Degeneration
NCT05222997
Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation
NCT00808197
Study of Dark Adaptation in Age-Related Macular Degeneration
NCT01352975
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
NCT04739319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cd35
cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Filled out informed consent
* Diagnosis of non-exudative/ exudative age related macular degeneneration
Exclusion Criteria
* Other acquired retinal/ macular
* Missing informed consent
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rudolf Foundation Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rudolf Foundation Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rudolf Foundation Clinic
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Haas P, Aggermann T, Nagl M, Steindl-Kuscher K, Krugluger W, Binder S. Implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2011 Sep;152(3):396-399.e1. doi: 10.1016/j.ajo.2011.02.017. Epub 2011 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK08010-VK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.